Cargando…

Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma

PURPOSE: To develop and validate a nomogram for individualized prediction of the long-term prognosis of patients with non-B, non-C hepatocellular carcinoma (NBNC-HCC) who underwent hepatectomy. MATERIALS AND METHODS: Five hundred ninety-four patients who met the criteria were included in the researc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Kongying, Huang, Qizhen, Huo, Yuting, Zeng, Jianxing, Ding, Zongren, Guo, Pengfei, Chen, Zhenwei, Zeng, Yongyi, Liu, Jingfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468529/
https://www.ncbi.nlm.nih.gov/pubmed/32943923
http://dx.doi.org/10.2147/CMAR.S257016
_version_ 1783578238713331712
author Lin, Kongying
Huang, Qizhen
Huo, Yuting
Zeng, Jianxing
Ding, Zongren
Guo, Pengfei
Chen, Zhenwei
Zeng, Yongyi
Liu, Jingfeng
author_facet Lin, Kongying
Huang, Qizhen
Huo, Yuting
Zeng, Jianxing
Ding, Zongren
Guo, Pengfei
Chen, Zhenwei
Zeng, Yongyi
Liu, Jingfeng
author_sort Lin, Kongying
collection PubMed
description PURPOSE: To develop and validate a nomogram for individualized prediction of the long-term prognosis of patients with non-B, non-C hepatocellular carcinoma (NBNC-HCC) who underwent hepatectomy. MATERIALS AND METHODS: Five hundred ninety-four patients who met the criteria were included in the research and randomly categorized into the training or validation cohort. The nomogram was constructed on the basis of the independent risk variables that were acquired via multivariate Cox proportional hazard regression analysis. Several complementary methods included the Harrell c-index, time-dependent areas under the receiver operating characteristic curve (tdAUC), and calibration plot, and the Kaplan–Meier curve with Log rank test were used to test predictive performance of the model. The clinical utility of the model was tested by the decision cure analysis (DCA). RESULTS: Tumor diameter, tumor number, elevated serum gamma-glutamyl transpeptidase (GGT) level, microvascular invasion (MVI), and macrovascular invasion were independent risk factors of prognosis of NBNC-HCC. C-indexes of the nomogram were 0.702 (95% confidence interval [CI], 0.662–0.741) in the training cohort and 0.700 (95% CI, 0.643–0.758) in the validation cohort, and median tdAUC values of the nomogram were 0.743 (range, 0.736–0.775) in the training cohort and 0.751 (range, 0.686–0.793) in the validation cohort, which were both higher than those in the conventionally used Barcelona Clinic Liver Cancer staging system, American Joint Committee on Cancer, and eighth edition and the model of Zhang et al. The calibration plot depicted a good consistency between prediction of the model and observed outcome. The Kaplan–Meier curve analysis showed that the model was able to separate patients into three distinct risk subgroups. The DCA analysis also demonstrated that the nomogram was clinically useful. CONCLUSION: We developed and validated a nomogram that was accurate and clinically useful in patients with NBNC-HCC who underwent hepatectomy.
format Online
Article
Text
id pubmed-7468529
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74685292020-09-16 Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma Lin, Kongying Huang, Qizhen Huo, Yuting Zeng, Jianxing Ding, Zongren Guo, Pengfei Chen, Zhenwei Zeng, Yongyi Liu, Jingfeng Cancer Manag Res Original Research PURPOSE: To develop and validate a nomogram for individualized prediction of the long-term prognosis of patients with non-B, non-C hepatocellular carcinoma (NBNC-HCC) who underwent hepatectomy. MATERIALS AND METHODS: Five hundred ninety-four patients who met the criteria were included in the research and randomly categorized into the training or validation cohort. The nomogram was constructed on the basis of the independent risk variables that were acquired via multivariate Cox proportional hazard regression analysis. Several complementary methods included the Harrell c-index, time-dependent areas under the receiver operating characteristic curve (tdAUC), and calibration plot, and the Kaplan–Meier curve with Log rank test were used to test predictive performance of the model. The clinical utility of the model was tested by the decision cure analysis (DCA). RESULTS: Tumor diameter, tumor number, elevated serum gamma-glutamyl transpeptidase (GGT) level, microvascular invasion (MVI), and macrovascular invasion were independent risk factors of prognosis of NBNC-HCC. C-indexes of the nomogram were 0.702 (95% confidence interval [CI], 0.662–0.741) in the training cohort and 0.700 (95% CI, 0.643–0.758) in the validation cohort, and median tdAUC values of the nomogram were 0.743 (range, 0.736–0.775) in the training cohort and 0.751 (range, 0.686–0.793) in the validation cohort, which were both higher than those in the conventionally used Barcelona Clinic Liver Cancer staging system, American Joint Committee on Cancer, and eighth edition and the model of Zhang et al. The calibration plot depicted a good consistency between prediction of the model and observed outcome. The Kaplan–Meier curve analysis showed that the model was able to separate patients into three distinct risk subgroups. The DCA analysis also demonstrated that the nomogram was clinically useful. CONCLUSION: We developed and validated a nomogram that was accurate and clinically useful in patients with NBNC-HCC who underwent hepatectomy. Dove 2020-08-24 /pmc/articles/PMC7468529/ /pubmed/32943923 http://dx.doi.org/10.2147/CMAR.S257016 Text en © 2020 Lin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lin, Kongying
Huang, Qizhen
Huo, Yuting
Zeng, Jianxing
Ding, Zongren
Guo, Pengfei
Chen, Zhenwei
Zeng, Yongyi
Liu, Jingfeng
Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma
title Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma
title_full Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma
title_fullStr Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma
title_full_unstemmed Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma
title_short Development and Validation of a Prognostic Nomogram to Predict the Long-Time Prognosis in Non-B, Non-C Hepatocellular Carcinoma
title_sort development and validation of a prognostic nomogram to predict the long-time prognosis in non-b, non-c hepatocellular carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468529/
https://www.ncbi.nlm.nih.gov/pubmed/32943923
http://dx.doi.org/10.2147/CMAR.S257016
work_keys_str_mv AT linkongying developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT huangqizhen developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT huoyuting developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT zengjianxing developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT dingzongren developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT guopengfei developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT chenzhenwei developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT zengyongyi developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma
AT liujingfeng developmentandvalidationofaprognosticnomogramtopredictthelongtimeprognosisinnonbnonchepatocellularcarcinoma